Connor, Clark & Lunn Investment Management Ltd. Spring Works Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	BUY	$24.1 - $39.66 $507,473 - $835,120	21,057 Added 64.26%	53,827 $1.54 Million
Q2 2022 Aug 05, 2022	BUY	$18.36 - $60.07 $601,657 - $1.97 Million	32,770 New	32,770 $807,000

Others Institutions Holding SWTX

# of Institutions

238

Shares Held

69.8M

Call Options Held

144K

Put Options Held

257K

Vanguard Group Inc Valley Forge, PA

6.71M
Shares

$262 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.62M
Shares

$219 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

3.84M
Shares

$150 Million
4.54% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.52M
Shares

$137 Million
0.01% of portfolio
Boxer Capital, LLC San Diego, CA

3.42M
Shares

$134 Million
5.82% of portfolio

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account